May 4 |
Pharma R&D productivity seen improving for the first time in years - Deloitte
|
May 4 |
Eli Lilly: Great Time To Divest Before It Potentially Crashes
|
May 4 |
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
|
May 4 |
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
|
May 4 |
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
|
May 3 |
Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
|
May 3 |
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
|
May 3 |
Eli Lilly Remains Expensive Here - Minimal Margin Of Safety
|
May 3 |
Analyst unveils Amgen stock price target after weight-loss drug data
|
May 3 |
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
|